Literature DB >> 10494225

Osteoporosis in older men: discovering when and how to treat it.

N A Siddiqui1, K R Shetty, E H Duthie.   

Abstract

Nearly 1.5 million American men age 65 and older have osteoporosis, and another 3.5 million are at risk. Hip fractures in older men have a higher mortality than in women and represent a growing medical problem. Glucocorticoid treatment, hypogonadism, and excessive alcohol consumption are important secondary etiologies for loss of bone mass in men. Detection of hypogonadism may be difficult, and testosterone replacement is indicated for only a well-defined subset of patients. Because of a lack of data on pathogenesis, risk factors, and therapeutic interventions in men, treatment decisions are usually based on extrapolation from studies in women. None of the medications approved by the FDA for the treatment of osteoporosis in postmenopausal women has been approved for use in older men, but physicians are prescribing bisphosphonates and calcitonin.

Entities:  

Mesh:

Year:  1999        PMID: 10494225

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  11 in total

1.  Age-and region-dependent changes in three-dimensional microstructural properties of proximal femoral trabeculae.

Authors:  W-Q Cui; Y-Y Won; M-H Baek; D-H Lee; Y-S Chung; J-H Hur; Y-Z Ma
Journal:  Osteoporos Int       Date:  2008-04-25       Impact factor: 4.507

2.  Rodent models of osteoporosis.

Authors:  Antonia Sophocleous; Aymen I Idris
Journal:  Bonekey Rep       Date:  2014-12-10

3.  Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures.

Authors:  S C Yang; Y C Chiu; P H Liu; T J Hsieh; Y H Kao; Y K Tu
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507

Review 4.  Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.

Authors:  Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio
Journal:  BMC Urol       Date:  2010-05-19       Impact factor: 2.264

6.  Daidzein administration positively affects thyroid C cells and bone structure in orchidectomized middle-aged rats.

Authors:  B Filipović; B Sosić-Jurjević; V Ajdzanović; D Brkić; M Manojlović-Stojanoski; V Milosević; M Sekulić
Journal:  Osteoporos Int       Date:  2009-10-27       Impact factor: 4.507

7.  A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.

Authors:  Sung Joon Hong; Kang Su Cho; Han Yong Cho; Hanjong Ahn; Choung-Soo Kim; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

8.  Use of bisphosphonates in prostate cancer: Current status.

Authors:  Rishi Nayyar; Narmada P Gupta
Journal:  Indian J Urol       Date:  2007-01

9.  Combined Effects of Eurycoma longifolia and Testosterone on Androgen-Deficient Osteoporosis in a Male Rat Model.

Authors:  Halimatun Saadiah Abdul Razak; Ahmad Nazrun Shuid; Isa Naina Mohamed
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-09       Impact factor: 2.629

10.  Eurycoma longifolia upregulates osteoprotegerin gene expression in androgen- deficient osteoporosis rat model.

Authors:  Ahmad Nazrun Shuid; Eman El-arabi; Nadia Mohd Effendy; Halimaton Saadiah Abdul Razak; Norliza Muhammad; Norazlina Mohamed; Ima Nirwana Soelaiman
Journal:  BMC Complement Altern Med       Date:  2012-09-12       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.